Hertzel Gerstein, a professor in the medicine department at McMaster University and a diabetes physician, stated that there are many possible explanations for this. Only one of these is that the drug was responsible for this reduction, he said in an emailed statement to Global News
Both hormones matter, but GLP-1 is likely the primary driver with GIP providing substantial enhancement
Ritterhoff, J
Because retatrutide has not received regulatory approval in the UK, there are no officially sanctioned dosage guidelines from NICE, the MHRA, or any equivalent body
More severe side effects are rare but can include low potassium, headache, dizziness, and chest pain
Always consult your prescriber or pharmacist with any questions